Indatuximab ravtansine (BT062) is an immunomodulatory and antineoplastic antibody-drug conjugate.
This is a chimerized anti-CD138 MAb (nBT062) associated with DM4 maytansinoid.
This is being investigated as part of the treatment for multiple myeloma.
Video Indatuximab ravtansine
Uji klinis
Multiple Myeloma
Initial data have been reported in 2013 from early stage clinical trials combined with Lenalidomide and Dexamethasone. Follow-up data reported "boosted efficacy" in December 2014.
More
By December 2014 it was in clinical trials for three negative metastatic breast cancer and metastatic bladder cancer.
Maps Indatuximab ravtansine
Action mechanism
CD138 (Syndecan-1) is highly expressed in various solid tumors and in hematologic malignancies, and is one of the most specific target targets for multiple myeloma cell (MM) identification. The antibody part binds to CD138 in the target cell and then DM4 kills the cell.
See also
- ImmunoGen, more on DM1/DM4 and links used in Indatuximab ravtansine
- Syndecan 1, a protein encoded by SDC1.
References
Source of the article : Wikipedia
0 Comments